4-[2-(4-Methoxyphenyl)ethoxy]benzaldehyde

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-[2-(4-Methoxyphenyl)ethoxy]benzaldehyde
• 英文别名: 4-(4'-methoxyphenylethoxy)benzaldehyde
• 化学式: C₁₆H₁₆O₃
• mdl: MFCD16330315
• 分子量: 256.301
• InChiKey: PUXVLWUQTAKYHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.187
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[2-(4-Methoxyphenyl)ethoxy]benzaldehyde 、 间氨基苯甲酸 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 甲苯 、 四氢呋喃 为溶剂， 反应 14.0h， 以96%的产率得到3-((4-(4-methoxyphenethoxy)benzyl)amino)benzoic acid
  参考文献：
  名称：

  Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders

  摘要：

  Peroxisome proliferator-activated receptor alpha (PPAR alpha) is expressed in retinal Muller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPAR alpha with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPAR alpha is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPAR alpha over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.

  DOI：

  10.1021/acs.jmedchem.9b01189
• 作为产物：
  描述：

  对甲氧基苯乙醇 在 三溴化磷 、 potassium carbonate 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[2-(4-Methoxyphenyl)ethoxy]benzaldehyde
  参考文献：
  名称：

  Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders

  摘要：

  Peroxisome proliferator-activated receptor alpha (PPAR alpha) is expressed in retinal Muller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPAR alpha with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPAR alpha is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPAR alpha over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.

  DOI：

  10.1021/acs.jmedchem.9b01189

文献信息

• DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS
  申请人：Takasu Hideki

  公开号：US20120283242A1

  公开（公告）日：2012-11-08

  The present invention provides a novel compound having an excellent antitumor effect. The compound of the present invention is represented by the following general formula (1) wherein R 1 and R 2 are aryl or the like; A is lower alkylene; Ring X is optionally substituted arylene; E is bond or lower alkenylene; Ring Y is optionally substituted heterocycloalkylene containing one or more nitrogen atoms, one of which is attached to the adjacent carbonyl group; G is —NH-G 2 -, —N(lower alkyl)-G 2 -, —NH—CH 2 -G 2 -, —N(lower alkyl)-CH 2 -G 2 - or —CH 2 -G 2 -, [wherein G 2 binds to R 2 , G 2 -R 2 is bond-R 2 , phenylene-G 3 -R 2 , phenylene-G 4 -O—R 2 , phenylene-G 5 -NH—R 2 , phenylene-G 6 -N(lower alkyl)-R 2 or quinolinediyl-O—R 2 , the phenylene of said phenylene-containing groups being optionally substituted with one or more substituents; G 3 -R 2 is —O-lower alkylene-R 2 or the like; G 4 -O— is lower alkylene-O— or the like; G 5 is lower alkylene; G 6 is lower alkylene].

  本发明提供了一种具有优异抗肿瘤效果的新型化合物。本发明的化合物由下述通式（1）表示，其中R1和R2为芳基或类似物；A为低级烷基；环X为可选取代的芳基；E为键或低级烯基；环Y为可选取代的杂环烷基，其中一个氮原子连接到相邻的羰基；G为—NH-G2-，—N(低级烷基)-G2-，—NH—CH2-G2-，—N(低级烷基)- -G2-或— -G2-，[其中G2与R2相连，G2-R2为键-R2，苯基-G3-R2，苯基-G4-O—R2，苯基-G5-NH—R2，苯基-G6-N(低级烷基)-R2或喹啉基-O—R2，所述苯基含有的苯基-含基团可选取代一个或多个取代基；G3-R2为—O-低级烷基-R2或类似物；G4-O—为低级烷基-O—或类似物；G5为低级烷基；G6为低级烷基]。
• GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd.

  公开号：EP3763728A1

  公开（公告）日：2021-01-13

  The present invention discloses glycopeptide compounds having activity of resisting drug-resistant bacteria, conforming to glycopeptide compounds represented by general formula (I), The present invention also provides a preparation method for and an application of the glycopeptide compounds. Upon testing, compared with a second-generation glycopeptide drug oritavancin, the glycopeptide antibiotic compounds have higher inhibition activity on drug-resistant bacterial strains, especially MRSA or VRE. Further testing shows that most of the glycopeptide compounds have safety higher than that of oritavancin and can be prepared into drugs for treating or preventing diseases caused by various bacterial infections, such as skin and soft tissue infections, meningitis, sepsis, pneumonia, arthritis, peritonitis, bronchitis, and empyema,

  本发明公开了具有抗耐药性细菌活性的糖肽化合物，符合通式（I）所代表的糖肽化合物、 本发明还提供了糖肽化合物的制备方法和应用。经测试，与第二代糖肽药物奥利他万星（oritavancin）相比，糖肽抗生素化合物对耐药菌株，尤其是 MRSA 或 VRE 具有更高的抑制活性。进一步的测试表明，大多数糖肽化合物的安全性高于奥利他万星，可以制备成药物，用于治疗或预防各种细菌感染引起的疾病，如皮肤和软组织感染、脑膜炎、败血症、肺炎、关节炎、腹膜炎、支气管炎和肺水肿、
• [EN] GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF<br/>[FR] COMPOSÉS GLYCOPEPTIDIQUES AYANT UNE ACTIVITÉ DE RÉSISTANCE À DES BACTÉRIES RÉSISTANTES AUX MÉDICAMENTS, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION<br/>[ZH] 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用
  申请人：SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO LTD

  公开号：WO2019170046A1

  公开（公告）日：2019-09-12

  本发明公开了一组具有抗耐药性细菌活性的糖肽类化合物，符合通式(Ⅰ)所示的糖肽类化合物。本发明还提供了上述糖肽类化合物的制备方法和应用。经测试，相较于二代糖肽类药物奥利万星，本发明的糖肽类抗生素化合物对耐药性菌株尤其是MRSA或VRE具有更高的抑制活性；进一步测试发现，本发明的绝大部分糖肽类化合物具有比奥利万星更高的安全性，可用于制成治疗或预防各种细菌性感染引起的如皮肤和软组织感染、脑膜炎、脓毒症、肺炎、关节炎、腹膜炎、支气管炎、积脓等疾病的药物。
• [EN] DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS<br/>[FR] DÉRIVÉS DE PYRIDINE DI-SUBSTITUÉS COMME AGENTS ANTICANCÉREUX
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2011093524A9

  公开（公告）日：2011-12-01
• EP3763728
  申请人：——

  公开号：——

  公开（公告）日：——